Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin.
Petrioli R, Pascucci A, Francini E, Marsili S, Sciandivasci A, Tassi R, Civitelli S, Tanzini G, Lorenzi M, Francini G. Petrioli R, et al. Among authors: pascucci a. Cancer Chemother Pharmacol. 2008 Jan;61(1):105-11. doi: 10.1007/s00280-007-0454-3. Epub 2007 Apr 12. Cancer Chemother Pharmacol. 2008. PMID: 17429632 Clinical Trial.
Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the Multidisciplinary Oncology Group on Gastrointestinal Tumors.
Petrioli R, Pascucci A, Francini E, Marsili S, Fiaschi AI, Civitelli S, Tanzini G, Battistelli S, Lorenzi M, Roviello F, Francini G; Multidisciplinary Oncology Group on Gastrointestinal Tumors. Petrioli R, et al. Among authors: pascucci a. Anticancer Drugs. 2008 Jan;19(1):91-6. doi: 10.1097/CAD.0b013e3282f21363. Anticancer Drugs. 2008. PMID: 18043134
Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin.
Petrioli R, Bargagli G, Lazzi S, Pascucci A, Francini E, Bellan C, Conca R, Martellucci I, Fiaschi AI, Lorenzi B, Francini G; Multidisciplinary Oncology Group in Gastrointestinal Tumors. Petrioli R, et al. Among authors: pascucci a. Anticancer Drugs. 2010 Mar;21(3):313-9. doi: 10.1097/CAD.0b013e328334d88a. Anticancer Drugs. 2010. PMID: 20016369 Clinical Trial.
CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab.
Petrioli R, Licchetta A, Roviello G, Pascucci A, Francini E, Bargagli G, Conca R, Miano ST, Marzocca G, Francini G; Multidisciplinary Oncology Group On Gastrointestinal Tumors. Petrioli R, et al. Among authors: pascucci a. Cancer Invest. 2012 Jan;30(1):65-71. doi: 10.3109/07357907.2011.629380. Cancer Invest. 2012. PMID: 22236191
Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study.
Petrioli R, Pascucci A, Conca R, Chiriacò G, Francini E, Bargagli G, Fiaschi AI, Manganelli A, De Rubertis G, Barbanti G, Ponchietti R, Francini G. Petrioli R, et al. Among authors: pascucci a. Br J Cancer. 2011 Feb 15;104(4):613-9. doi: 10.1038/bjc.2011.5. Epub 2011 Feb 1. Br J Cancer. 2011. PMID: 21285986 Free PMC article. Clinical Trial.
Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer.
Francini F, Pascucci A, Bargagli G, Francini E, Conca R, Miano ST, Martellucci I, Migali C, Gotti G, Fiaschi AI, Cozzolino A, Petrioli R. Francini F, et al. Among authors: pascucci a. Int J Clin Oncol. 2011 Jun;16(3):264-9. doi: 10.1007/s10147-010-0179-x. Epub 2011 Jan 18. Int J Clin Oncol. 2011. PMID: 21240683 Clinical Trial.
36 results